News
AVGR
1.590
-6.47%
-0.110
Avinger, Inc. Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-the-Market Under Nasdaq Rules
Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the closi...
ACCESSWIRE · 1d ago
Avinger to Announce Second Quarter 2022 Results on August 11
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its f...
ACCESSWIRE · 4d ago
Avinger stock slides on ~$5M securities offering
Avinger (NASDAQ:AVGR) shares dropped ~8% pre-market on ...
Seekingalpha · 5d ago
Avinger Announces $5M Registered Direct Offering
https://www.accesswire.com/710827/Avinger-Announces-5-Million-Registered-Direct-and-Private-Placement-Offerings-Priced-At-the-Market-Under-Nasdaq-Rules
Benzinga · 5d ago
Avinger Announces $5 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced that it has entered into ...
ACCESSWIRE · 5d ago
Wall Street Set for Gains as White House Weighs Cutting Tariffs on Chinese Goods
MT Newswires · 05/23 09:23
Top Premarket Decliners
MT Newswires · 05/23 08:20
BRIEF-Avinge Entered Into At Market Offering Agreement
reuters.com · 05/20 21:24
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million.
Benzinga · 05/11 16:25
Avinger stock slumps after Q1 earnings miss, revenue hit due to Omicron; B. Riley cuts PT
Shares of Avinger (NASDAQ:AVGR) have fallen 23.9% to $1.78 in Wednesday morning trade, after the medical device company's Q1 2022 earnings missed estimates. AVGR posted Q1 GAAP EPS of -$2.33 which missed expectations
Seekingalpha · 05/11 15:32
Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates
Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:55
Recap: Avinger Q1 Earnings
Avinger (NASDAQ:AVGR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Avinger missed estimated earnings by 99.15%, reporting an EPS of $-2.33 versus an estimate of $...
Benzinga · 05/10 21:52
BRIEF-Avinger Reports Qtrly Net Loss Per Share Of $2.33
reuters.com · 05/10 21:47
Avinger Q1 Sales $1.90M Miss $2.05M Estimate
Avinger (NASDAQ:AVGR) reported quarterly sales of $1.90 million which missed the analyst consensus estimate of $2.05 million by 7.32 percent. This is a 25.75 percent decrease over sales of $2.56 million the same period
Benzinga · 05/10 20:38
Avinger GAAP EPS of -$2.33 misses by $1.15, revenue of $1.9M misses by $0.15M
Avinger press release (NASDAQ:AVGR): Q1 GAAP EPS of -$2.33 misses by $1.15. Revenue of $1.9M (-25.8% Y/Y) misses by $0.15M. During the quarter, the company received FDA 510((k)) clearance for
Seekingalpha · 05/10 20:18
-- Earnings Flash (AVGR) AVINGER Posts Q1 Revenue $1.9M, vs. Street Est of $2.05M
MT Newswires · 05/10 16:15
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
Avinger Q1 2022 Earnings Preview
Avinger (NASDAQ:AVGR) is scheduled to announce Q1 earnings results on Tuesday, May 10th, after market close. The consensus EPS Estimate is -$1.18 vs. -$0.07 year ago and the consensus Revenue
Seekingalpha · 05/09 21:35
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 23:45
More
Webull provides a variety of real-time AVGR stock news. You can receive the latest news about Avinger Inc through multiple platforms. This information may help you make smarter investment decisions.
About AVGR
Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its image-guided Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. It has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris SV (Small Vessel).